网络编辑平台

编辑出版

《中国临床医学》编辑部

  地址:上海市枫林路179号18号楼501室

  邮编:200032

  电话:021-60267570

  邮箱:(1)zglcyx@126.com; (2)zglcyxfb@126.com

作者园地

在线调查

您喜欢的投稿方式调查


相关下载

您所在位置:首页->过刊浏览->第19卷第4期


论著:信号转导转录激活因子3抑制剂WP1066对肝细胞肝癌生物学特性影响的研究
Effects of an Inhibitor of Signal Transducer and Activator of Transcription 3, WP 1066, on the Biological Characteristics of Hepatocellular Carcinoma
张巨波 郭坤 陈漪 葛宁灵 任正刚
点击:2581次 下载:0次
作者单位:复旦大学附属中山医院肝肿瘤内科
中文关键字:肝癌;抑制剂;信号转导转录激活因子3;增殖;侵袭
英文关键字:Hepatocellular carcinoma; Inhibitor; Signal transducer and activator of transcription 3; Proliferation; Invasion
中文摘要:目的:探讨信号转导转录激活因子3(signal transducer and activator of transcription 3,STAT3)的抑制剂WP1066在体外对人肝细胞肝癌(hepatocellular carcinoma,HCC)增殖、侵袭能力的影响以及在体内应用时对HCC的抑制效果。方法:采用蛋白印迹、Transwell等方法检测在不同恶性潜能的人HCC细胞株中STAT3总蛋白及磷酸化水平的差异,观察应用WP1066后人HCC细胞株MHCC 97H的增殖以及侵袭能力的改变。皮下接种MHCC 97H细胞株建立裸鼠的HCC模型后,观察WP1066对肿瘤生长的影响。结果:STAT3磷酸化水平在恶性潜能高的人HCC细胞株中显著高于恶性潜能低的HCC细胞株;WP1066能显著抑制MHCC 97H的增殖和侵袭。在裸鼠HCC模型中,WP1066能有效地抑制HCC生长。结论:WP1066能抑制STAT3磷酸化水平而有效抑制HCC增殖和侵袭。
英文摘要:Objective: To explore the effects of an inhibitor of signal transducer and activator of transcription 3 (STAT3), WP1066, on the proliferation and invasion of hepatocellular carcinoma (HCC) cells in vitro and in vivo.Methods: The expression level and phosphorylation level of STAT3 in HCC cell lines with different malignant potential were detected by Western blotting and Transwell method. The antitumor activities of WP1066 and related mechanisms were studied in HCC cell line MHCC 97H and also in a subcutaneous HCC model in nude mice. Results: STAT3 phosphorylation level was significantly higher in HCC cell lines with higher malignant potential. WP1066 significantly inhibited cell proliferation and invasion in MHCC 97H. WP1066 also significantly inhibited the growth of tumor in nude mice HCC model. Conclusions: WP 1066 can suppress the proliferation and invasion of HCC through inhibition of the phosphorylation level of STAT3.
读者评论

      读者ID: 密码:   
我要评论:
主办单位:复旦大学附属中山医院
联系地址:上海市枫林路179号18号楼501室 邮编:200032
联系电话:021-60267570 E-Mail:(1)zglcyx@126.com; (2)zglcyxfb@126.com
版权所有©2009-2010 《中国临床医学》杂志编辑部 沪ICP备1103249号
本系统由北京菲斯特诺科技有限公司设计开发
您是本站第1269991名访问者